| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5578 | Ym-90k | Novel AMPA receptor antagonist |
|
| DCC5579 | Yml220 | Potent and selective microbicidal agent against wild type (wt) HIV-1, NNRTI-, NRTI-, PRI-resistant mutants |
|
| DCC5580 | Ynt-1310 | Water-soluble analog of YNT-707, acting as a potent orexin 1 receptor (OX1R) antagonist |
|
| DCC5581 | Ynt-707 | Novel potent orexin 1 receptor (OX1R) antagonist |
|
| DCC5582 | Yoyo-1 | DNA-intercalating dye as sensitive amyloid probe |
|
| DCC5583 | Ysy01a | Novel Proteasome Inhibitor, Enhancing Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells, inducing cell cycle arrest on G2 phase in MCF-7 cells via ERα and PI3K/Akt pathways |
|
| DCC5584 | Yt-146 | Selective A 2A receptor agonist |
|
| DCC5585 | Yu2534342249 | Novel γ-lactam pyrazolidinone, targeting penicillin-binding proteins (PBPs) and incorporating a siderophore moiety to facilitate uptake into the periplasm, being effective against multidrug-resistant gram-negative Bacilli |
|
| DCC5586 | Yw2065 | Novel inhibitor of Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin |
|
| DCC5587 | Yycg Inhibitor 16 | Novel YycG inhibitor, inhibiting planktonic cells of E. faecalis, including the vancomycin- or linezolid-resistant strains |
|
| DCC5588 | Yycg Inhibitor 62 | Novel YycG inhibitor, significantly inhibited biofilm formation in static and dynamic conditions |
|
| DCC5589 | Yz-2-90 | Novel activator of JNK, binding directly to microtubules, inducing ERK-mediated mitotic arrest and subsequent apoptosis |
|
| DCC5590 | Z118332870 | Novel first-in-class inhibitor of BRD4 and EGFR kinase |
|
| DCC5591 | Z1241145220 | Novel potent ligand of σ2 receptor (K i =7nM) |
|
| DCC5592 | Z1913661252 | Novel riboswitch activator, binding ZTP riboswitches, and activating transcription more strongly than ZMP in vitro |
|
| DCC5593 | Z4446724338 | Novel potent dual σ1/2 ligand (σ1 K i =5nM, σ2 K i =3nM), showing anti-allodynic in a model of neuropathic pain |
|
| DCC5594 | Z56965384 | Novel USP10 inhibitor |
|
| DCC5595 | Zarilamide | Inhibitor of the nuclear division in germinating zoospore cysts of Phytophthora capsici via destruction of the microtubule cytoskeleton, and a consequent inhibition of mitosis |
|
| DCC5596 | Zatosetron | Serotonin 5-HT3 receptor antagonist |
|
| DCC5597 | Zbh-1205 | Novel camptothecin derivative, revealing potent antitumor activities mainly through cell apoptosis pathway, being more effective than CPT-11 and SN38 at inhibiting topoismerase-1 |
|
| DCC5598 | Zd1611 | Endothelin Receptor Antagonist |
|
| DCC5599 | Zd2138 | Potent, orally active inhibitor of 5-lipoxygenase (5-LO) |
|
| DCC5600 | Zd6126 | Vascular targeting agent (VTA) |
|
| DCC5601 | zd6169 | Potassium channel opener |
|
| DCC5602 | Zdhhc Substrate Peptide | ZDHHC (zinc finger Asp-His-His-Cys) substrate peptide, a 15-mer peptide sequence from KRas4a plus two tryptophan residues |
|
| DCC5603 | Zdlt-1 | Novel potent HDAC inhibitor with IC50 values for class I HDACs 1, 2, and 3 below 4 nM, and IC50 for HDAC6 at 6 nM. |
|
| DCC5604 | Z-don-val-pro-leu-ome | Site specific inhibitor of tissue transglutaminase |
|
| DCC5605 | Zdwx-25 | Novel daul inhibitor of GSK-3β (IC 50 = 71 nM) and DYRK1A (IC 50 = 103 nM) with good blood-brain barrier penetrability, inhibiting hyperphosphorylation of tau protein in okadaic acid (OKA)-induced SH-SY5Y cells |
|
| DCC5606 | Zfh7116 | Novel inhibitor of pro-HGF activation |
|
| DCC5607 | Zg-2033 | Novel Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist |
|
